AMD3100 (plerixafor), a selective CXCR4 antagonist and disrupts the CXCR4/CXCL12 signaling and has shown antitumor activity in preclinical lung cancer models (Wang et al., 2016). This evidence concerns the gene CXCL12 and lung carcinoma.